Serious adverse events occurred in @ ( @ % ) patients in the treatment-naive group ; @ ( @ % ) non-responders , and @ ( @ % ) ineligible , intolerant , or ineligible and intolerant patients ; adverse events leading to discontinuation ( most commonly reversible increases in alanine or aspartate aminotransferase ) occurred in six ( @ % ) , two ( @ % ) , and two ( @ % ) patients , respectively , with no deaths recorded .